做多
Is ARIA drug approval enough for a gap fill?
How are you going to trade this breakout inside the gap? goo.gl/jGvOaX
Ariad Pharmaceuticals Inc., the cancer-drug maker that had lost about 70 percent of its value this year, will return its only product (cleared last year for certain types of leukemia) to the U.S. market after regulators approved a new prescribing and risk management plan.
Sales of the drug were halted in the U.S. in October after regulators saw an increased risk of blood clots.
businessweek.com/news/2013-12-20/ariad-gets-u-dot-s-dot-approval-to-bring-cancer-drug-back-to-market-1
If October's gap down is filled, a long position opened today with a $4.50 stop loss has a potential Risk/Reward ratio of 2.
What do you think of the gap at the ARIA stock chart?
Ariad Pharmaceuticals Inc., the cancer-drug maker that had lost about 70 percent of its value this year, will return its only product (cleared last year for certain types of leukemia) to the U.S. market after regulators approved a new prescribing and risk management plan.
Sales of the drug were halted in the U.S. in October after regulators saw an increased risk of blood clots.
businessweek.com/news/2013-12-20/ariad-gets-u-dot-s-dot-approval-to-bring-cancer-drug-back-to-market-1
If October's gap down is filled, a long position opened today with a $4.50 stop loss has a potential Risk/Reward ratio of 2.
What do you think of the gap at the ARIA stock chart?
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。